6 research outputs found
Drugs modulating the L-arginine:NO:cGMP pathway – current use in therapy
Nitric oxide (NO) is a relatively novel messenger that plays a significant role in a wide range of physiological processes. Currently, it is known that, both, lack and excess of NO can cause diseases, thus a lot of substances have been discovered and utilized which can change the concentration of this molecule within the organism. The aim of the present work is to provide an overview of currently used agents modulating the L-arginine:NO:cGMP pathway, as well as to summarize current understanding of their pharmacological profiles. Nowadays, most of these agents are employed particularly in the treatment of cardiovascular diseases. Further studies can hold promise for enhancing the therapeutic equipment for a variety of other impairments, such as osteoporosis, and also in treatments of the central nervous system
New Drugs - From Necessity to Delivery
How to get a new drug to market? How much time does it take to go from the idea to implementation? In this study we followed the path drugs take from synthesis to introduction to the market. In doing so, articles in the PubMed and the Google Scholar database have been analyzed using the keywords: drug development, drug design, lead compound, preclinical trials, clinical trials. The available literature was subjectively selected due to its usefulness in the topic. Based on the obtained articles, we presented the stages that a would-be drug takes on the way from the idea to marketing. Herein, it is underlined that the process of creating new drugs is long, extremely labor-intensive, and involves many restrictions in the context of the use of animals, as well as human
Research in the Field of Drug Design and Development
The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5–10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society’s insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrád group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic
Synthesis, in vitro and in vivo pharmacological evaluation of serotoninergic ligands containing an isonicotinic nucleus
Isonicotinamide derivatives, linked to an arylpiperazine moiety, were prepared and their affinity to 5-
HT1A, 5-HT2A and 5-HT2C receptors were evaluated. The combination of structural elements (heterocyclic
nucleus, alkyl chain and 4-substituted piperazine) known to play critical roles in affinity for serotoninergic
receptors and the proper selection of substituents led to compounds with high specificity and
affinity towards serotoninergic receptors. In binding studies, several molecules showed high affinity in
nanomolar and subnanomolar range at 5-HT1A, 5-HT2A and 5-HT2C receptors and moderate or no affinity
for other relevant receptors (D1, D2, a1 and a2). N-(3-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)propyl)
isonicotinamide (4s) with Ki ÂĽ 0.130 nM, was the most active and selective derivative for the 5-HT1A
receptor compared to other serotoninergic, dopaminergic and adrenergic receptors. Compound 4o,
instead, showed 5-HT2A affinity values in subnamolar range. Moreover, the compounds having better
affinity and selectivity binding profile towards 5-HT1A and 5-HT2A receptors were selected in order to be
tested by in vitro and in vivo assays to determine their functional activity